Type 2 diabetes

group, D. I. A. L. 2 working. (2022). Estimating individual lifetime risk of incident cardiovascular events in adults with type 2 diabetes: an update and geographical calibration of the DIAbetes Lifetime perspective model (DIAL2). Eur J Prev Cardiol. http://doi.org/10.1093/eurjpc/zwac232
Brunetti, V. C., St-Jean, A., Dell'Aniello, S., Fisher, A., H. Y. Yu, O., Bugden, S. C., et al. (2022). Characteristics of new users of recent antidiabetic drugs in Canada and the United Kingdom. Bmc Endocr Disord, 22, 241. http://doi.org/10.1186/s12902-022-01140-1
Bidulka, P., Mathur, R., Lugo-Palacios, D. G., O'Neill, S., Basu, A., Silverwood, R. J., et al. (2022). Ethnic and socioeconomic disparities in initiation of second-line antidiabetic treatment in people with type 2 diabetes in England: a cross-sectional study. Diabetes Obes Metab. http://doi.org/10.1111/dom.14874
Sarodnik, C., Rasmussen, N. H., Bours, S. P. G., Schaper, N. C., Vestergaard, P., Souverein, P. C., et al. (2022). The incidence of fractures at various sites in newly treated patients with type 2 diabetes mellitus. Bone Rep, 17, 101614. http://doi.org/10.1016/j.bonr.2022.101614
Xu, Z., Arnold, M., Sun, L., Stevens, D., Chung, R., Ip, S., et al. (2022). Incremental value of risk factor variability for cardiovascular risk prediction in individuals with type 2 diabetes: results from UK primary care electronic health records. Int J Epidemiol. http://doi.org/10.1093/ije/dyac140
Idris, I., Zhang, R., Mamza, J. B., Ford, M., Morris, T., Banerjee, A., & Khunti, K. (2022). Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a UK clinical setting. Diabetes Obes Metab. http://doi.org/10.1111/dom.14799
Alkabbani, W., Zongo, A., Minhas-Sandhu, J. K., Eurich, D. T., Shah, B. R., Alsabbagh, M. W., & Gamble, J. M. (2021). Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections: A Propensity Score-matched Population-based Cohort Study. Can J Diabetes. http://doi.org/10.1016/j.jcjd.2021.12.005
Mueller, A. M., Meier, C. R., Jick, S. S., & Schneider, C. (2022). Characterization of the deterioration of diabetes control in patients with a subsequent diagnosis of pancreatic cancer: A descriptive study. Pancreatology. http://doi.org/10.1016/j.pan.2022.03.012
Foch, C., Allignol, A., Hohenberger, T., Boutmy, E., Schaefer, S., & Hostalek, U. (2022). Effectiveness of bisoprolol versus other β-blockers and other antihypertensive classes: a cohort study in the Clinical Practice Research Datalink. J Comp Eff Res. http://doi.org/10.2217/cer-2021-0305
Pradhan, R., Yu, O., Platt, R. W., & Azoulay, L. (2022). Long-Term patterns of cancer incidence among patients with and without type 2 diabetes in the United Kingdom. Diabetes Res Clin Pract, 185, 109229. http://doi.org/10.1016/j.diabres.2022.109229